Appoints Brian Strem as President & CEO; signs non-binding LOI to acquire Bayon Therapeutics

KIORA PHARMACEUTICALS INC

Brian M. Strem appointed President and CEO effective July 26, 2021; Franz Obermayr returns to EVP Clinical Development.
Strem receives $400K annual base salary, target bonus of 50% of base, and option to purchase 100K shares vesting over 3 years.
EyeGate enters non-binding term sheet to acquire Bayon Therapeutics for closing consideration of 50K shares and earnout up to $7.1M or ~2.2M shares.
Strem is co-founder of Bayon and owns ~28% equity; transaction subject to definitive agreement and milestone conditions.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brian M. Strem

Class I Director

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2021-07-26
Filed: July 26, 2021, 7:59 PM ET

the Board, upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board from seven to eight members, and appointed Dr. Strem as a Class I director to fill the resulting vacancy, in each case effective as of the Effective Date

Appointed

Brian M. Strem

President and Chief Executive Officer

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2021-07-26
Filed: July 26, 2021, 7:59 PM ET

On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President and Chief Executive Officer of the Company, effective as of July 26, 2021 (the “Effective Date”).

Role change

Franz Obermayr

EVP Clinical Development

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2021-07-26
Filed: July 26, 2021, 7:59 PM ET

Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian M. Strem was appointed as Class I Director at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: Class I Director

Exact text from the filing

the Board, upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board from seven to eight members, and appointed Dr. Strem as a Class I director to fill the resulting vacancy, in each case effective as of the Effective Date

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President and Chief Executive Officer of the Company, effective as of July 26, 2021 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Franz Obermayr changed role as EVP Clinical Development at KIORA PHARMACEUTICALS INC.

Action: resumed
Role: EVP Clinical Development

Exact text from the filing

Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.

View on SEC.gov

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-21-095852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.